Beijing Hotgen Biotech Co

Beijing Hotgen Biotech Co OCF Margin

The Operating Cash Flow Margin of Beijing Hotgen Biotech Co (688068.SS) as of Nov 5, 2026 is -20.45 %. In the previous year, Operating Cash Flow Margin was -7.27 % — a change of 181.08% (lower).

OCF Margin

-20.45 %

YoY

181.08%

Last updated:

Operating Cash Flow Margin of Beijing Hotgen Biotech Co is 2025 -20.45 % . Operating Cash Flow Margin of Beijing Hotgen Biotech Co was 2024 -7.27 % . It decreases by 181.08% lower compared to the previous year.

The Beijing Hotgen Biotech Co OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
29.41 CNY
Jan 1, 2019
9.21 CNY
Jan 1, 2020
32.06 CNY
Jan 1, 2021
49.25 CNY
Jan 1, 2022
27.52 CNY
Jan 1, 2023
-4.63 CNY
Jan 1, 2024
-7.27 CNY
Jan 1, 2025
-20.45 CNY
The Beijing Hotgen Biotech Co OCF Margin history
YEAROCF MarginYoY
-20.45 %+181.08%
-7.27 %+56.97%
-4.63 %-116.84%
27.52 %-44.13%
49.25 %+53.64%
32.06 %+248.19%
9.21 %-68.70%
29.41 %+82.10%
16.15 %-56.66%
37.27 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Beijing Hotgen Biotech Co Stock analysis

What does Beijing Hotgen Biotech Co do? Beijing Hotgen Biotech Co., Ltd. generates revenue through the development and manufacturing of in-vitro diagnostic, point-of-care-testing, and biodefense products. The firm's product portfolio primarily consists of in vitro diagnostic reagents, in vitro diagnostic instruments, and biological raw materials. These offerings are designed to address clinical needs in areas such as liver cancer, hepatitis, cardiovascular and cerebrovascular diseases, and inflammatory infections. Additionally, the products serve public safety applications including biosafety, food safety, and disease control and emergency response. The company operates in both domestic and overseas markets, selling its solutions to entities involved in clinical healthcare and public safety sectors. By providing specialized diagnostic tools and biological materials, Beijing Hotgen Biotech Co., Ltd. supports medical diagnosis and emergency response efforts globally. The business model relies on the direct sale of these manufactured goods to customers who require advanced diagnostic capabilities for disease detection and safety monitoring. Beijing Hotgen Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Beijing Hotgen Biotech Co stock

Operating Cash Flow Margin of Beijing Hotgen Biotech Co is -20.45 % in 2025.

Operating Cash Flow Margin of Beijing Hotgen Biotech Co changed from -7.27 % to -20.45 %, representing a 181.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Beijing Hotgen Biotech Co since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Beijing Hotgen Biotech Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Beijing Hotgen Biotech Co

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Beijing Hotgen Biotech Co